Atlas Trials

Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Clinical trial NCT01399593 · TERMINATED

Trial details

NCT number
NCT01399593
Sponsor
Alexion Pharmaceuticals, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Antibody Mediated Rejection
Start date
2011-11-02
Primary completion
2014-05-13
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.